2024
NSP-CT-022: Cognition Product Pilot Study. Winter 2024 - Present. (Principal Investigator [PI])²
NSP-CT-021: Metabolic Health 1: PowerLine Evaluation - a Proof of Concept Study. Winter 2024 - Present. (PI)²
2023
EFE1: ERr 731® Formulation Evaluation; A Comparison of Enteric coated and Micro-coated ERr 731® Formulations. Spring - Summer 2023 (Primary Investigator [PI].⁴
NSP-CT-020: Evaluation of Salivary Nitrite Levels and Cardiovascular Health after Oral Administration of Power Beets in Healthy Volunteers. Winter 2023. (PI)²
2021
LH7: LIFEHOUSE 2.0, a Lifestyle Intervention and Functional Evaluation: a Health OUtcomes SurvEy 2.0: Description of Overall Study (TENT) and Community Health Umbrella. Spring 2021 - Spring 2023 (PI).⁴
2020
LH6: LIFEHOUSE, a Lifestyle Intervention and Functional Evaluation: a Health OUtcomes SurvEy: Description of the Tent Bucket - Immune Support. Fall 2020 - Spring 2021 (PI).⁴
2019
Resistant Starch Blend Gastrointestinal Impact. Summer 2019 - Fall 2020.⁴
Testing of Glycemic Index, Glycemic Load, and Glycemic Load Equivalents in a Range of Nutritional Shake Products. Summer - Fall 2020.⁴
Prospective Tolerability Assessment of a Probiotic Dietary Supplement, HD Probiotic, Study Protocol Summer 2019.⁴
NSP-CT-017: Measurements of Salivary Nitrite Level after Oral Administration of Cardiovascular Nutraceuticals in Healthy Volunteers. Winter 2019.²
2018
LH5: LIFEHOUSE, a Lifestyle Intervention and Functional Evaluation: a Health OUtcomes SurvEy: Description of Gastrointestinal Health Umbrella. LH4: LIFEHOUSE, a Lifestyle Intervention and Functional Evaluation: a Health OUtcomes SurvEy: Description of Reproductive Health Umbrella. LH3: LIFEHOUSE, a Lifestyle Intervention and Functional Evaluation: a Health OUtcomes SurvEy: Description of Metabolic Health Umbrella. LH2: LIFEHOUSE, a Lifestyle Intervention and Functional Evaluation: a Health OUtcomes SurvEy: Description of Immune Health Umbrella. LH1: LIFEHOUSE, a Lifestyle Intervention and Functional Evaluation: a Health OUtcomes SurvEy: Description of Overall Study and Study Umbrellas (Wellness, Dental Health, Neurological Health). Summer 2018 - Summer 2019 (PI).⁴
PLX1: A Study to Examine Correlations Between Lifestyle Factors, Genomic Data, Physical Exam Findings and Biomarkers. Winter - Spring 2018 (PI).⁴
NSP-CT-015: Evaluation of Various Curcumin formulations for Bio-availability and Ex vivo Anti-inflammatory and Anti-oxidative Properties in Healthy Volunteers; Winter - Spring 2018 (PI).²
2017
NSP-CT-012: Safety Evaluation of a Diet and Nutritional Supplementation Program for Support of Balanced Bowel Function in Healthy Volunteers; Summer - Fall 2017 (PI).²
2016
NSP-CT-011: Clinical Assessment of Blood EPA and DHA Levels after Multiple Doses of Two Cod Liver Oil Formulations; Summer - Winter 2016 (PI).²
NSP-CT-010: Safety Evaluation of a Lifestyle Modification Program for Healthy Weight and Cardiometabolic Function – Phase 2; Spring - Fall 2016 (PI).²
2015
NSP-CT-009: Clinical Assessment of CYP450 Activities Before and After Nutritional Supplements; Winter -Spring 2015 (PI).²
NSP-CT-008: Clinical Study Determination of Glycemic Responses and Indices of Nutritional Supplements; Winter -Spring 2015 (PI).²
HI-CT-144: Safety Evaluation of a Proprietary Nutraceutical for Healthy Cardiometabolic Function; Summer 2015.³
NSP-CT-004: Safety Evaluation of a Lifestyle Modification Program for Healthy Weight and Cardiometabolic Function; Spring - Fall 2015 (PI).²
NSP-CT-003: Evaluation of Dose Effect of a Unique Formulation for Maintenance of Healthy Bowel Function; Winter 2015 (PI).²
2014
GIS4: A Pilot Study to Explore the Glycemic Response to Two Unique Medical Foods: For Diabetes Mellitus in Healthy Subjects; Spring 2014 (PI).¹
GIS3: Evaluation of Efficacy and Glycemic Response Subjects at Risk for Type 2 Diabetes Mellitus: Comparing a medical food with three foods in a double-blinded, randomized, crossover fashion; Spring 2014 (PI).¹
GIS2: Determination of Glycemic Index of Two Medical Foods and Two Foods for Diabetes Mellitus; Winter 2014 (PI).¹
2013
OCS1: OsteoVantiv Case Series for Subjects with Mild to Moderate Joint Discomfort; Fall 2013 (PI).¹
GIS1: Determination of Glycemic Index of Four Carbohydrate Mixtures; Fall 2013 (PI).¹
NEU1: Depression Case Series (Botanical/Nutraceutical Use, Blended Lifestyle Support and Nutritional Change; Fall 2013 (PI).¹
NEU1: Anxiety Case Series (Botanical/Nutraceutical Use, Blended Lifestyle Support and Nutritional Change; Fall 2013 (PI).¹
EST2: Estrovera Experience Trial: Post Marketing Evaluation of Use and Safety of a unique Siberian Rhubarb Extract in Healthy Women; Winter 2013 (PI).¹
DIA5: Pilot Evaluation of Efficacy and Glycemic Response in Insulin Resistant Subjects; Winter 2013 (PI).¹
WLM3: 52-week Pilot Trial Extension to Evaluate the Effects of PR-557 on Weight Loss Maintenance in Healthy Subjects; Winter 2013 (PI).¹
2012
WLM2: 12-week Experience Study to Observe the Effects of a Novel Lifestyle Change Program on Weight Loss in Obese Subjects; Summer 2012 (PI).¹
POT2: A Double-blind, Placebo-controlled Trial of a Cholesstrinol™ HPE at 2 Doses in Conjunction with Fish Oil Supplementation; Summer 2012 (PI).¹
COR1: Nutritional Supplement for Cardiovascular Health: Case Series to Establish Proof of Principle: Spring 2012 (PI).¹
ARG4: Evaluation of Arginine Plus with Magnesium, Beet Powder and Thiamine mononitrate (PR-610) in Hypertensive Subjects; Spring 2012 (PI).¹
EVV5: An Ex-vivo analysis of Two Unique Pterostilbene/THIAA Supplements and a Curcumin Supplement in Healthy Subjects; Spring 2012 (PI).¹
ARG3: Evaluation of Arginine Plus with Magnesium, Beet Powder and Thiamin mononitrate (PR-607) in Healthy Subjects; Spring 2012 (PI).¹
EVV4: A Pilot Study to Assess the Safety and Tolerability of Pterostilbene Nutritional Supplements; Spring 2012 (PI).¹
ARG2: Evaluation of Arginine Plus with Magnesium and Beet powder (PR-606) in Healthy Subjects; Spring 2012 (PI).¹
ARG1: Evaluation of Arginine Plus with Magnesium in Healthy Subjects; Spring 2012 (PI).¹
EVV3: Evaluation of a New Method and a Measurement of the ex Vivo effect of THIAA in Healthy Subjects; Spring 2012 (PI).¹
POT1: Nutritional Supplements for CV Health: Sequential Case Series to Establish Proof of Principle; Winter 2012 (PI).¹
EVV2: Evaluation of a New Method and a Comparison of the ex Vivo effect of THIAA and Prednisone in Healthy Subjects; Winter 2012 (PI).¹
DIA4: Pilot Evaluation of Efficacy and Glycemic Response in Insulin Resistant Subjects: Comparing two medical foods and one nutritional supplement in a single-blinded, randomized, crossover fashion; Winter 2012 (PI).¹
2011
GLP2: Observation of Effect of Fish Oil on GLP-1Secretion in Healthy Subjects; Fall 2011 (PI).¹
PYM1: A Pilot Study to Assess the Safety and Efficacy of a Novel Nutraceutical for Support of General Health Biomarkers in Healthy Subjects, Fall 2011.¹
GLP1: Observation of Effect of Tetra-hydro-iso-alpha acids (PR-580) on GLP-1Secretion in Healthy Subjects; Fall 2011 (PI).¹
THX8: Comparison of Two Dosing Forms of Tetra-hydro-iso-alpha acids, Rosemary and Oleanolic Acid in a Healthy Subject, Summer 2011 (PI).¹
THX7: Comparison of Two Dosing Forms of Tetra-hydro-iso-alpha acids, Rosemary and Oleanolic Acid in a Healthy Subject, Summer 2011 (PI).¹
WLM1: 64-week Pilot trial to Evaluate the Effects of PR-557 on Weight Loss and Weight Loss Maintenance in Obese Subjects, Spring 2011(PI).¹
THX6: Comparison of Two Dosing Forms of Tetra-hydro-iso-alpha acids, Rosemary and Oleanolic Acid in a Healthy Subject, Spring 2011 (PI).¹
EVV1: Comparison of the bioavailability and effect of PR-549 and PR-550 in Healthy Subjects, Spring 2011 (PI).¹
CUR1: Comparison of Two Dosing Forms of Curcumin (PR-547 and PR-548) and THIAA (PR-546) in Healthy Subjects, Winter 2011 (PI).¹
THX5: Comparison of Two Dosing Forms of Tetra-hydro-iso-alpha acids in Healthy Subjects, Winter 2011 (PI).¹
2010
HOM1: Validation of Reference Lab for Homocysteine testing, Winter 2010 (PI).¹
THX4: Comparison of Two Dosing Forms of Tetra-hydro-iso-alpha acids in Healthy Subjects, Fall 2010 (PI).¹
CVN2: An open-label, pilot study to evaluate the safety of a novel nutraceutical, PR-524, Fall 2010 (PI).¹
MED1: A Pilot Study to Assess the Safety and Efficacy of a Novel Nutraceutical for Support of General Health Biomarkers and Genomic Stability in Healthy Subjects, Fall 2010 (PI).¹
DIA3: Evaluation of the glycemic response in three different cohorts: comparing five medical foods and one nutritional supplement in a single-blinded, randomized, crossover fashion, Summer 2010 (PI).¹
SDN1: Single Dose Niacin Tolerability Study, Summer 2010 (PI).¹
COG1: Randomized, double-blind, placebo-controlled, three-arm, parallel group study to evaluate the safety and efficacy of Cognisure, Summer 2010(PI).¹
VID2: Pilot study to assess the sa1fety, tolerance, and efficacy of two unique formulations of Vitamin D3 in healthy subjects, Spring 2010 (PI).¹
CVN1: Pilot Trial to evaluate the effect of a novel nutraceutical on markers of cardiovascular health and endothelial function as measured by bio-markers and flow-mediated vasodilation (FMD) in patients with hyperlipidemia, Spring 2010 (PI).¹
2009
EVE1: Open-label trial to assess the safety and tolerance of a unique nutraceutical, ERr 731®, in symptomatic peri-menopausal, menopausal, and post-menopausal women, Fall 2009 (PI).¹
FMD 2.0: Pilot Study to Evaluate the Effect of a Novel Nutraceutical on Endothelial Function, as measured by Flow-mediated Vasodilation (FMD) in Subjects with Well-controlled Type II Diabetes Mellitus, Fall 2009 (PI).¹
DIA2: Single arm, open-label study to assess the effect of a reformulated medical food and lifestyle change on amelioration of blood sugar in subjects with less than optimally controlled Type II Diabetes Mellitus, Fall 2009 (PI).¹
VID1: Pilot study to assess the safety and tolerance of a 5,000 IU formulation of Vitamin D3 [25-(OH) Vitamin D] in healthy subjects, Summer 2009 (PI).¹
FMD1.7: A Methodological Evaluation of Flow Mediated Vasodilation in Healthy Volunteers, Spring 2009 (PI).¹
DIA1: Single arm, open-label study to assess the effect of a newly reformulated medical food on amelioration of blood sugar control in subjects with less than optimally controlled Type II Diabetes Mellitus, Spring-Summer 2009 (PI).¹
DTX6: Open-label Study to Assess the Effect of a Novel Nutraceutical on Toxic Element Detoxification, Spring-Summer 2009 (PI).¹
TOU2: Evaluation of Efficacy of a novel Medical Food containing a Fermented Soybean Extract, Spring 2009 (PI).¹
NIA1: Dose-escalation Study to Assess Safety and Tolerability for A Niacin-Fish Oil Combination Product, Spring 2009 (PI).¹
THX3: Safety Evaluation of an Enriched THIAA Compound, Winter 2009 (PI).¹
THX2: Safety Evaluation of an Enriched THIAA Compound, Winter 2009 (PI).¹
TOU1: Evaluation of Efficacy of Fermented Soybean Extract, Winter 2009 (PI).¹
THX1: Dose Ranging Evaluation of THIAA, Winter/Spring 2009 (PI).¹
2008
FMD1.5: Pilot study to evaluate the effect of a novel nutraceutical on endothelial function, as measured by flow-mediated vasodilation (FMD) in healthy volunteers, Fall 2008 (PI).¹
NTE1: Evaluation and Validation of In-Office testing Kit for Toxic Elements, Summer 2008 (PI).¹
DTX5: Open-label, controlled study to assess the effect of a novel dietary program on clinical symptoms and markers of biotransformation and detoxification in subjects with fibromyalgia, Summer 2008 (PI).¹
CMS1: Open-label study to assess the effect of a low-allergy-potential dietary program on cardiometabolic risk factors in subjects with metabolic syndrome, Summer 2008 (PI).¹
FMD1: A Methodological Evaluation of Flow Mediated Vasodilation in Healthy Volunteers, Spring 2008 (PI).¹
HMS3a: Evaluation of long-term effects of 2 dietary programs on cardiovascular risk factors in subjects with metabolic syndrome, Winter 2008.¹
2007
Detox 2: Open-label Study to Assess the Effect of a Novel Nutraceutical upon Biotransformation and Detoxification Biomarkers, Fall 2007 (PI).¹
IR07: Open-label study to assess the effect of a novel dietary program on cardiovascular risk factors in menopausal and postmenopausal females with metabolic syndrome, Fall 2007 (PI).¹
OSECM1: Individual Case Management (ICM) Series - Effectiveness of EC Matrixx for Relief of Musculoskeletal Symptoms, Fall 2007 (PI).¹
Detox 1: Pilot Study to Assess the Effect of a Novel Nutraceutical upon Biotransformation and Detoxification Biomarkers, Fall 2007 (PI).¹
DTX Urine pH 3 and 4: Assessment of urine pH after ingestion of an investigational detoxification product, Summer/Fall 2007.¹
OSMS1: Open-label case series to assess the effect of Metagenics FirstLine Therapy® Therapeutic Lifestyle Program, including a novel medical food, on markers of Metabolic Syndrome, Summer/Fall 2007.¹
Colostrinin Dose Ranging Study, Fall 2007 (PI).¹
HM1: Single-blind, randomized, five-arm, placebo-controlled trial to assess the effect of two novel nutraceuticals, low glycemic load diet, and exercise on markers of bone health in menopausal women with and without metabolic syndrome, Summer/Fall/Winter 2007 (PI).¹
OSJR2: Individual Case Management (ICM) Series - Effectiveness of Meta061 for Relief of Joint Discomfort, Winter/Spring/Summer 2007 (Primary Investigator [PI]).¹
2006
CALP4: Comparison of Gastrointestinal Effects of a Botanical Anti-Inflammatory vs. an Anti-Inflammatory Medication as Measured by Fecal Calprotectin, Summer 2006.¹
HMS3: Controlled study to compare the effects of 2 dietary programs on cardiovascular risk factors in subjects with metabolic syndrome, Summer/Fall 2006.¹
¹ Study conducted by the Functional Medicine Research Center in Gig Harbor, Washington 98332; sponsored by Metagenics, Inc. in Aliso Viejo, California 92656.
² Study conducted by the Hughes Center for Research and Innovation in Lehi, Utah 84043; sponsored by Nature’s Sunshine Products, Inc. in Spanish Fork, Utah 84660.
³ Study conducted by the Hypertension Institute in Nashville, Tennessee 37069; sponsored by Thorne Research, Inc. in Dover, ID 83825.
⁴ Study conducted by the Personalized Lifestyle Medicine Clinic in Gig Harbor, Washington 98332; sponsored by Metagenics, Inc. in Aliso Viejo, California 92656.